PepWisePepWise
App Store Google Play
Start free

Peptide Encyclopedia / Hexarelin

Encyclopedia

Hexarelin

Hexarelin is a potent growth hormone-releasing peptide and ghrelin-receptor agonist that prompts pituitary GH release and can shift cortisol and prolactin. Human data stay limited to early-phase and animal work, and it trades as a research chemical, not an FDA-approved drug. Educational only, not medical advice.

Track Hexarelin →Dose tools
CategoryGrowth Hormone
Half-life55 minutes to ~2 hours
Regulatory statusNot FDA-approved.

Mechanism

A potent synthetic growth hormone-releasing peptide / ghrelin-receptor agonist that stimulates pituitary GH release; reported to also influence ACTH, cortisol, and prolactin.

Half-life

~55 minutes to ~2 hours; uncertain.

Regulatory status

Not FDA-approved. Considered a research chemical / gray-market substance in the US. Prohibited by WADA.

Safety

Water retention, increased appetite, possible cortisol/prolactin elevation, injection-site reactions; potential receptor desensitization. Long-term safety not established.

Evidence

Limited human data; mostly early-phase/animal studies and anecdotal use.

Track Hexarelin in PepWise

Log every dose and injection site, get the reconstitution and units math automatically, follow your cycle, and record how you feel, then export a provider report. Hexarelin tracker, free to start.

Sources

  1. Imbimbo BP, et al. Growth hormone-releasing activity of hexarelin in humans: a dose-response study. Eur J Clin Pharmacol. 1994;46(5):421-425. https://pubmed.ncbi.nlm.nih.gov/7957521/
  2. Arvat E, et al. Effects of GHRP-2 and hexarelin on GH, prolactin, ACTH and cortisol in man. Peptides. 1997;18(6):885-891. https://pubmed.ncbi.nlm.nih.gov/9285939/
  3. Bodart V, et al. CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart. Circ Res. 2002;90(8):844-849. https://pubmed.ncbi.nlm.nih.gov/11988484/
  4. Rahim A, Shalet SM. Does desensitization to hexarelin occur? Growth Horm IGF Res. 1998;8 Suppl A:141-143. https://pubmed.ncbi.nlm.nih.gov/10990150/
  5. Rahim A, O'Neill PA, Shalet SM. Growth hormone status during long-term hexarelin therapy. J Clin Endocrinol Metab. 1998;83(5):1644-1649. https://pubmed.ncbi.nlm.nih.gov/9589671/

PepWise is an informational and educational tracking tool, not medical advice and not a medical device. Hexarelin may be experimental, restricted, or prescription-only; many research peptides are not FDA-approved. Consult a licensed healthcare provider before starting, changing, or stopping any protocol. Operated by STC Consulting, Inc.